New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT07334119
Summary
This is the first study in people to test an experimental drug called MT-304 for advanced cancers that have a protein called HER2. The main goals are to check if the drug is safe, find the best dose, and see if it helps control the cancer. About 60 adults will receive MT-304 by itself or combined with another cancer drug, and doctors will closely monitor them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
RECRUITINGWaratah, New South Wales, 2298, Australia
Contact
Contact Phone: •••-•••-••••
-
Cancer Research SA Pty Ltd
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-••••
Contact
-
Icon Cancer Centre South Brisbane
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact Phone: •••-•••-••••
Contact
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-••••
Contact
-
Scientia Clinical Research Ltd
RECRUITINGRandwick, New South Wales, 2031, Australia
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.